Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System

• Главные авторы: Giuseppe Cicala (Автор), Giulia Russo (Автор), Vincenza Santoro (Автор), Tindara Franchina (Автор), Nicola Silvestris (Автор), Mariacarmela Santarpia (Автор), Edoardo Spina (Автор), Maria Antonietta Barbieri (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2024-09-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

<b>Background/Objectives</b>: Monoclonal antibodies (mAbs) have revolutionized multiple myeloma (MM) treatment. However, post-marketing data on their neuropsychiatric safety are limited. This study aimed to evaluate neuropsychiatric adverse events (AEs) related to mAbs used for MM throug...